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SilibininAbstract Curcumin is a functional food, which provides a wide range of health beneﬁts including
anti-cancer activity and consid2;ered as a suitable alternative for chemotherapeutic agents. How-
ever, cancer cells exhibit resistance to most chemotherapeutic agents including curcumin due to
overexpression of adenosine triphosphate (ATP)-binding cassette transporter proteins in the cancer
cell membrane, which decrease the intracellular concentration of chemotherapeutic agents. Simi-
larly, most chemotherapeutic agents including curcumin experience lack of cancer cell targeting,
lack of aqueous solubility, rapid systemic clearance, intestinal metabolism and hepatic metabolism.
These limitations hinder the clinical usefulness of curcumin in the treatment of multidrug-resistant
cancers. In this article, we propose curcumin–piperine, or curcumin–quercetin or curcumin–silibinin
dual drug-loaded nanoparticulate combination therapy to target and treat multidrug-resistant can-
cers. The proposed dual drug-loaded nanoparticulate combination is expected to reverse the mul-
tidrug resistance, prevent the rapid systemic clearance, prevent the intestinal and the hepatic
metabolism, increase the aqueous solubility, enhance the bioavailability, target the cancer cells, pro-
duce a synergistic anti-cancer effect and enhance the efﬁcacy of curcumin in the treatment of mul-
tidrug-resistant cancers.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd. Open access under 7440311.
om (C. Moorthi).
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16 C. Moorthi, K. KathiresanIntroduction
Functional foods are those food itemswhich provide health ben-
eﬁts beyond their nutritive value and are considered as a suitable
alternative for potent drugs with severe systemic toxicities such
as chemotherapeutic agents. Of all functional foods, polyphe-
nols attracted many researchers as they possess a wide spectrum
of health beneﬁts including anti-cancer activity [1,2].
One such polyphenol is curcumin, which is a hydrophobic
orange-yellow crystalline phytochemical isolated from various
sources including Curcuma longa [3]. Curcumin is safe, as it is
well tolerated even at a dose of 12 g day1 in phase-I clinical
trials and has also been declared as GRAS (generally regarded
as safe) by United States Food and Drug Administration
[1,4–6].
Due to its diverse molecular targets, curcumin exhibits a wide
range of pharmacological activities and is used in the treatment
of various diseases including cataract, wound, gall stones, al-
lergy, pancreatitis, gastric ulcer, inﬂammatory bowel disease, fe-
ver, acquired immune deﬁciency syndrome, psoriasis,
Alzheimer’s disease, scleroderma, hypothyroidism, cystic ﬁbro-
sis, atherosclerosis, myocardial infarction, osteoporosis, lung
diseases, malaria, arthritis, leishmaniasis, diabetes mellitus, mul-
tiple sclerosis, epilepsy, Parkinson’s disease and cancer [1–4].
Curcumin exhibits its therapeutic potential (Fig. 1) against
a wide spectrum of cancers including breast cancer, oral can-
cer, oesophageal cancer, lymphoma, gastric cancer, cervical
cancer, intestinal cancer, multiple myeloma, hepatic cancer,
pancreatic cancer, leukaemia, colorectal cancer, bladder can-
cer, melanoma, kidney cancer, ovarian cancer, prostate cancer,
sarcoma, thymic cancer, uterine cancer, skin cancer, neurolog-Figure 1 Curcumin exhibits its anti-cancer activity through variety of
Protein p16, Protein p53, Protein p14ARF and Cyclin-dependent
upregulating Protein p53, Bax, Bad, Bim and down regulation of B-cell
factor kappa-light-chain-enhancer of activated B cells (NF-jB) andmam
NF-jB leads to suppression of many NF-jB regulated genes involved in
the lysosomal proteases, phosphatases and lipases. Curcumin inhibit angical cancer, bone cancer, brain cancer and head and neck squa-
mous cell carcinoma [7–10].
However, most cancer cells show resistance towards most
conventional chemotherapeutic agents including curcumin
due to overexpression of drug efﬂux ATP-binding cassette
transporter proteins including P-glycoprotein (P-gp), multi-
drug resistance protein 1 (MDRP1), multidrug resistance pro-
tein 2 (MDRP2) and breast cancer resistance protein (BCRP),
which drive the drug out of cancer cells and decrease intracel-
lular drug concentration. Similarly, most conventional chemo-
therapeutic agents including curcumin experience lack of
cancer cell targeting, lack of aqueous solubility, rapid clear-
ance from the systemic circulation, intestinal metabolism and
hepatic metabolism [1,11]. These limitations hinder the clinical
usefulness of curcumin in the treatment of multidrug-resistant
cancers.
In recent years, various approaches have been tried to over-
come these limitations, which are tabulated in Table 1 [12–24].
However, in this article, we propose a dual drug-loaded nanop-
articulate combination therapy containing curcumin and a bio-
enhancer such as piperine, quercetin or silibinin, which can sig-
niﬁcantly overcome the multidrug resistance and other limita-
tions including lack of cancer cell targeting, lack of aqueous
solubility, rapid systemic clearance, intestinal metabolism and
hepatic metabolism and is expected to enhance the efﬁcacy of
curcumin in the treatment of multidrug-resistant cancers.
Hypotheses
We propose curcumin–piperine, or curcumin–quercetin or cur-
cumin–silibinin dual drug-loaded nanoparticulate combinationmechanisms. Curcumin arrest the cancer cell cycle by upregulating
kinase (CDK) inhibitors. Curcumin stimulate the apoptosis by
lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), Nuclear
malian target of rapamycin (mTOR). However, down regulation of
tumorigenesis. Curcumin modulate the autophagy by upregulating
iogenesis andmetastasis by suppression of variety of growth factors.
Table 1 Signiﬁcant approaches to overcome the limitations of curcumin.
S.No. Approaches Result Ref.
1 Transferrin-mediated solid lipid nanoparticles Target curcumin in the MCF-7 breast cancer cells [12]
2 c-cyclodextrin liposomal nanoparticles Increase the water solubility of curcumin [13]
3 Human Serum Albumin Nanoparticles Increase the water solubility of curcumin [14]
4 PLGA encapsulated nanoparticles Increase the oral bioavailability of curcumin [15]
5 Poly (lactide-co-glycolide) /polyethylene glycol encapsulated
nanoparticulate
Enhance the cellular uptake of curcumin [16]
6. Transferrin-superparamagnetic iron oxide nanoparticles Target curcumin in chronic myeloid leukemia cancer cells [17]
7 PVP capped gold nanoparticles Increase the oral bioavailability of curcumin [18]
8 Biocompatible thermoresponsive polymeric nanoparticles Target curcumin in cancer cells [19]
9 Apolipoprotein-E3 mediated poly(butyl)cyanoacrylate
nanoparticles
Increase the oral bioavailability of curcumin [20]
10 Dextran sulphate chitosan nanoparticles Increase the oral bioavailability of curcumin [21]
11 Chitosan nanoparticles Improve the bioavailability and chemical stability of curcumin [22]
12 Chitosan/ poly(caprolactone) nanoparticles Improve the cellular uptake of curcumin [23]
13 PCL-PEG-PCL triblock copolymeric nanoparticles Improve the water solubility and the bioavailability of curcumin [24]
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cyclodextrin as a stabiliser.
We hypothesise the following:
(1) Bio-enhancer and poloxamer in the proposed dual drug-
loaded nanoparticulate combination therapy can signif-
icantly modulate the ATP-binding cassette transporter
proteins and thereby reverse multidrug resistance.
(2) Nanosizing of the drugs in the proposed dual drug-
loaded nanoparticulate combination therapy is expected
to increase the aqueous solubility and thereby increase
the bioavailability of both curcumin and bio-enhancer.
(3) Bio-enhancer in the proposed dual drug-loaded nanop-
articulate combination therapy is expected to mini-
mise/prevent intestinal and hepatic metabolism by a
competitive mechanism and thereby increase the bio-
availability of curcumin.
(4) Poloxamer in the proposed dual drug-loaded nanopar-
ticulate combination therapy is expected to adsorb onto
the surface of curcumin and bio-enhancer and prevent
the rapid systemic clearance and thereby increase the
bioavailability of both curcumin and bio-enhancer.
(5) Nanosizing of the drugs in the proposed dual drug-
loaded nanoparticulate combination therapy is expected
to enhance the reactability of both curcumin and bio-
enhancer to speciﬁc molecular targets and produces
required pharmacological actions at much reduced dose
levels.
(6) Bio-enhancer in the proposed dual drug-loaded nanop-
articulate combination therapy also exhibits a wide spec-
trum of pharmacological activities including anti-cancer
activity and is expected to produce a synergistic anti-
cancer effect with curcumin.
(7) Nanosizing of the drugs in the proposed dual drug-
loaded nanoparticulate combination therapy is expected
to target cancer cells by a passive mechanism through an
enhanced permeability and retention effect and thereby
enhance the anti-cancer activity of curcumin and bio-
enhancer.
(8) Beta cyclodextrin in the proposed dual drug-loaded
nanoparticulate combination therapy is expected toincrease the aqueous solubility, prevent photodegrada-
tion, provide stability during storage and also prevent
drug–drug/drug–excipient interactions.Evaluation of hypotheses
The proposed hypotheses can be tested by the following
studies
(1) We propose to compare the anti-cancer potential of
pure curcumin, a mixture of curcumin with bio-enhan-
cer and the proposed dual drug-loaded nanoparticu-
late combination on multidrug-resistant cancer cell
lines using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay, or the sulforho-
damine B assay or the clonogenic assay. This study
is required to conﬁrm the enhancement of anti-cancer
activity of the proposed dual drug-loaded nanopartic-
ulate combination by modulating the ATP-binding
cassette transporter proteins in comparison with pure
curcumin and a mixture of curcumin with bio-
enhancer.
(2) We propose to compare the solubility of pure curcumin
and the proposed dual drug-loaded nanoparticulate
combination. This study is required to conﬁrm the
enhancement of the water solubility of the proposed
combination in comparison with pure curcumin.
(3) We propose to administer the pure curcumin, a mix-
ture of pure curcumin with bio-enhancer and proposed
dual drug-loaded nanoparticulate combination at the
same dose level to three different animal groups and
collect the blood samples at ﬁxed intervals and analyse
the blood samples for the presence of curcumin and
bio-enhancer using a validated high-performance
liquid chromatography (HPLC) method and calculate
the bioavailability of curcumin and bio-enhancer. This
study is required to conﬁrm the enhancement of the
bioavailability of the proposed combination in com-
parison with pure curcumin and pure curcumin with
bio-enhancer.
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pure curcumin, mixture of pure curcumin with bio-
enhancer and the proposed dual drug-loaded nanopar-
ticulate combination after maintaining the samples at
40 ± 2 C/75 ± 5% RH (relative humidity) for
6 months. This study is required to conﬁrm the stability
enhancement of the proposed combination in compari-
son with pure curcumin and a mixture of curcumin with
bio-enhancer.
(5) We propose to compare the anti-cancer potential of
pure curcumin, mixture of curcumin with bio-enhancer
and the proposed dual drug-loaded nanoparticulate
combination on various cancer cell lines at various
lower dose levels using the MTT assay, or the sulfo-
rhodamine B assay or a clonogenic assay. This study
is required to conﬁrm the enhancement of anti-cancer
activity of the proposed combination at reduced dose
levels in comparison with pure curcumin and a mix-
ture of curcumin with bio-enhancer.
(6) We propose to compare the anti-cancer potential of
pure curcumin, mixture of curcumin with bio-enhancer
and the proposed dual drug-loaded nanoparticulate
combination in living female athymic NCr-nu/nu mice
bearing subcutaneous multidrug-resistant breast cancer
(MDA-MB-435S MDR) tumour xenografts. This
study is required to conﬁrm the enhancement of
anti-cancer activity of the proposed combination by
reversing the multidrug resistance in comparison with
pure curcumin and mixture of curcumin with bio-
enhancer.
Discussion
A novel approach to target and treat multidrug-resistant can-
cers using dual drug-loaded nanoparticulate combination has
been proposed in this article.
According to Noyes–Whitney’s equation, size reduction
to the nanometre range can signiﬁcantly increase the interfa-
cial surface area, thereby increasing the rate of dissolution
and aqueous solubility, which in turn leads to enhancement
of drug bioavailability. However, increase in interfacial sur-
face area also increases the reactability of a drug to speciﬁc
molecular targets and enhances its pharmacological action
[25,26]. Most chemotherapeutic agents including curcumin
and bio-enhancers including piperine, quercetin and silibinin
are hydrophobic in nature, which signiﬁcantly contributes to
low bioavailability. Hence, based on the above facts we pro-
pose to use a nanoparticulate drug delivery system, which
not only improves the bioavailability but also enhances the
reactability of both curcumin and bio-enhancer to speciﬁc
molecular targets.
Natural bio-enhancers such as piperine, quercetin and sil-
ibinin can signiﬁcantly suppress the drug-metabolising en-
zyme cytochrome P450 3A, hepatic glucuronidation and
intestinal glucuronidation and thereby increase the bioavail-
ability of a drug. These bio-enhancers also reverse multidrug
resistance by modulating ATP-binding cassette transporter
proteins such as P-gp, MDRP1, MDRP2 and BCRP. More-over, these natural bio-enhancers also exhibit a wide spec-
trum of pharmacological activities including anti-cancer
activity [27–30]. Hence, based on the above facts we propose
to use these bio-enhancers to reverse multidrug resistance, to
increase the bioavailability of curcumin by preventing hepa-
tic and intestinal metabolism and to produce a synergistic
anti-cancer effect with curcumin.
Opsonin is a blood serum protein that binds to hydropho-
bic drug particles and gets easily recognised by the macro-
phages of the mononuclear phagocytic system, which in turn
leads to the removal of the hydrophobic drug particles from
the circulatory system. However, adsorption or grafting of
polyethylene glycol or a polyethylene glycol-containing
copolymer such as poloxamer to the surface of a hydrophobic
drug provides a hydrophilic coat, which in turn repels the
opsonin proteins via steric repulsion, thereby blocking the ﬁrst
step in the opsonisation process and increasing the bioavail-
ability of the drug. However, poloxamer also possess an ability
to modulate the ATP-binding cassette transporter proteins
such as P-gp, MDRP1, MDRP2 and BCRP, thereby reversing
the multidrug resistance [11,31]. Hence, based on the above
facts we propose to use poloxamer 188 as a polymer to reverse
multidrug resistance and to prevent the rapid systemic clear-
ance of curcumin and bio-enhancer.
In contrast to normal tissues, tumour tissues are highly
permeable with a gap ranging between 200 and 600 nm in
diameter and they also lack a lymphatic system, which is
responsible for the drainage of macromolecules. This defec-
tive architecture of tumour tissues allows the long-circulating
nanoparticles with size <200 nm to accumulate in tumour
tissues via enhanced permeability and retention effect
[11,32]. Hence, based on the above facts we propose to de-
sign a nanoparticulate drug delivery system for the combina-
tion of curcumin and bio-enhancer.
Cyclodextrins are cyclic oligosaccharides with a lipophilic
central cavity and a hydrophilic outer surface. They are mainly
used as complexing agents to increase the aqueous solubility of
hydrophobic drugs, thereby increasing drug bioavailability.
However, complexation with cyclodextrin also reduces gastro-
intestinal drug irritation, increases drug stability and prevents
drug–drug/drug–excipient interactions [33]. Hence, based on
the above facts we propose to use beta cyclodextrin to prevent
drug–drug/drug–excipient interactions, increase the drug sta-
bility, increase the aqueous solubility and thereby increase
the bioavailability of curcumin and bio-enhancer.Conclusion
In this article, we propose a novel approach to target and
treat multidrug-resistant cancers using a dual drug-loaded
nanoparticulate combination. The proposed nanoparticulate
combination is expected to reverse the multidrug resistance,
increase the water solubility, prevent the rapid systemic
clearance, prevent the intestinal and hepatic metabolism,
enhance the bioavailability and enhance the cancer cell
targeting. The proposed dual drug-loaded nanoparticulate
combination seems to have potential in treating multidrug-
resistant cancers.
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What do we already know about the subject?
Cancer cells exhibit resistance to most chemotherapeu-
tic agents due to overexpression of ABC transporter pro-
teins, which decrease the intracellular concentration of
drug. Similarly, most chemotherapeutic agents experience
lack of cancer cell targeting, lack of aqueous solubility, ra-
pid systemic clearance, intestinal metabolism and hepatic
metabolism.
What does your proposed theory add to the current
knowledge available, and what beneﬁts does it have?
The proposed nanoparticulate combination reverses
multidrug resistance, prevents rapid systemic clearance,
increases aqueous solubility, prevents intestinal and hepa-
tic metabolism, targets cancer cells through the enhanced
permeability and retention effect, enhances drug reactabil-
ity and produces an synergistic anti-cancer effect.
Among numerous available studies, what special further
study is proposed for testing the idea?
We propose to study the effect of the proposed dual
drug loaded nanoparticulate combination on protein
p53, protein p16, B-cell lymphoma 2 (Bcl-2) gene, vascu-
lar endothelial growth factor (VEGF), cyclooxygenase-2
(COX-2), matrix metalloproteinases (MMPs), mamma-
lian target of rapamycin (mTOR) and tumour necrosis
factor-a (TNF-a). We also propose to perform in-vitro
anti-cancer activity for the proposed combination on can-
cer stem cells.Acknowledgement
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